α-Glucosidase-IN-21

Modify Date: 2024-01-03 22:32:49

α-Glucosidase-IN-21 structure	Common Name	α-Glucosidase-IN-21
	CAS Number	321686-01-5	Molecular Weight	389.51
	Density	N/A	Boiling Point	N/A
	Molecular Formula	C₂₄H₂₃NO₂S	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of α-Glucosidase-IN-21

α-Glucosidase-IN-21 (Compound 2B) is a potent, orally active α-glucosidase inhibitor with an IC50 of 2.62 μM. α-Glucosidase-IN-21 shows anti-diabetic activity[1].

Name	α-Glucosidase-IN-21

Description	α-Glucosidase-IN-21 (Compound 2B) is a potent, orally active α-glucosidase inhibitor with an IC50 of 2.62 μM. α-Glucosidase-IN-21 shows anti-diabetic activity[1].
Related Catalog	Research Areas >> Metabolic Disease
In Vivo	α-Glucosidase-IN-21 (Compound 2B; 10 and 20 mg/kg; p.o.; daily, for 4 weeks) has anti-diabetic activity in Streptozocin (HY-13753)-induced diabetic rats[1]. α-Glucosidase-IN-21 (10 and 20 mg/kg; p.o.; once) significantly decreases the serum glucose level after the administration of glucose (3 g/kg, oral) in rats[1]. α-Glucosidase-IN-21 (2000 mg/kg; p.o.; daily, for 2 weeks) demonstrates no mortality in mice[1]. Animal Model: Male Wistar albino rats (170-200 g), Streptozotocin-induced diabetes model[1] Dosage: 10 and 20 mg/kg Administration: Oral administration; daily, for 4 weeks Result: Decreased the level of blood glucose, reversed Streptozocin-induced body weight loss. Showed antihyperlipidemic effects on Streptozotocin-induced diabetes, reduced to a significant level of serum biomarkers.
References	[1]. Mehmood R, et al. Synthesis of Novel 2, 3-Dihydro-1, 5-Benzothiazepines as α-Glucosidase Inhibitors: In Vitro, In Vivo, Kinetic, SAR, Molecular Docking, and QSAR Studies. ACS Omega, 2022 Aug 17.

Molecular Formula	C₂₄H₂₃NO₂S
Molecular Weight	389.51